trial · primary record
Sarilumab
Melanoma
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 105 |
| Primary completion | 2028-03-17 |
| Primary endpoint | Number of Grades 3-5 Treatment-Related Immune-Related Adverse Events (irAE) per NCI CTCAE v 5.0 Criteria |
| Registry ID | NCT05428007 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:39:32.070Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05428007
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Sarilumab · compound